Pivotal bioVenture Partners Investment Advisor’s Recursion Pharmaceuticals RXRX Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.83M	Hold	595,518	–	–	0.65%	12
2025 Q4	$2.44M	Hold	595,518	–	–	0.94%	10
2025 Q3	$2.91M	Hold	595,518	–	–	1.68%	8
2025 Q2	$3.01M	Hold	595,518	–	–	1.87%	8
2025 Q1	$3.15M	Hold	595,518	–	–	2.55%	6
2024 Q4	$4.03M	Buy	+595,518	New	+$4M	2.72%	6

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's RXRX Position: Q1 2026 in Review

Pivotal bioVenture Partners Investment Advisor held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 595,518 shares worth $1.83M. The position accounts for 0.65% of the portfolio, ranked #12.

Pivotal bioVenture Partners Investment Advisor first reported a position in RXRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.03M in Q4 2024. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Pivotal bioVenture Partners Investment Advisor held 595,518 shares of Recursion Pharmaceuticals worth $1.83M as of Q1 2026.
Pivotal bioVenture Partners Investment Advisor left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
Recursion Pharmaceuticals made up 0.65% of Pivotal bioVenture Partners Investment Advisor's portfolio in Q1 2026, its #12 holding.
Pivotal bioVenture Partners Investment Advisor first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Pivotal bioVenture Partners Investment Advisor's Recursion Pharmaceuticals position peaked at $4.03M in Q4 2024.
335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2026, filed 14 May 2026.